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FLUDARABINE-BASED NON-MYELOABLATIVE STEM CELL TRANSPLAN-
TATION IN A PATIENT WITH SICKLE CELL DISEASE AND RENAL FAIL-
URE: CLINICAL OUTCOME AND PHARMACOKINETIC COMPARISON TO
PATIENTS WITH NORMAL RENAL FUNCTION
Spasojevic, I.1, Morris, A.3, Long, G.3, Gasparetto, C.3, Sullivan, K.3,
Chute, J.3, Telen, M.2, Chao, N.3, Rizzieri, D.3, Horwitz, M.3 1De-
partment of Medicine; 2Division of Hematology; 3Division of Cellular
Therapy, Duke University School of Medicine, Durham, NC.
End-organ damage is common in adult patients with Sickle Cell
Disease (SCD), therefore an effective non-myeloablative approach
to allogeneic stem cell transplantation (SCT) would be ideal. Flu-
darabine is a component of most non-myeloablative conditioning
regimens. Since 40% of the active metabolite, 2-ﬂuoro-ara-A (F-
Ara-A), is cleared by the kidneys, use in patients with renal insuf-
ﬁciency or renal failure is hazardous. We report the outcome of
two adult SCD patients who underwent non-myeloablative SCT
from their HLA-identical matched siblings on an NHLBI-spon-
sored clinical trial. Patient #1 is a 21 year-old male with normal
renal function and patient #2 a 27 year old with dialysis-dependent
end-stage renal disease. Conditioning consisted of Total Body
Irradiation 200cGy followed by Fludarabine (Pt #1: 30 mg/m2, Pt
#2: 24 mg/m2) Cyclophosphamide 500mg/m2, both given over four
days and Campath 1-H 100mg over 5 days. Mycophenolate
Mofetil 2 grams/day was given for 100 days. Patient #1 and #2
received peripheral blood stem cell grafts containing 21106 and
19106 CD34 cells/kg, respectively. Patient #2 underwent 6
hours of conventional hemodialysis using an F200 dialyzer, 12
hours after each Fludarabine dose. Plasma samples from patient #2
and two additional non-SCD patients with normal renal function
undergoing stem cell transplantation using the same chemotherapy
preparative regimen were collected over 24 hours after doses 1 and
4 of Fludarabine. F-Ara-A was measured by a validated LC/
MS/MS assay. Both SCD patients achieved full donor erythroid
chimerism and stable mixed lymphoid and myeloid chimerism
(donor CD15/CD3; Pt #1 89%/87% 14 months post-transplant,
Pt #2 86%/45% 6 months post transplant). Neither patient devel-
oped graft vs host disease, neurological complications or any other
SCD-related complications following transplantation. Both have
normal blood counts and are on no immunosuppressive medica-
tions. F-Ara-A pharmacokinetic parameters obtained using non-
compartmental analysis are given in the table. With a 20% dose
reduction followed by intensive daily dialysis, we achieved Fludara-
bine levels that are nearly identical to that achieved in patients with
normal renal function. This allowed for robust donor stem cell
engraftment without Fludarabine-related toxicity. We conclude
that non-myeloablative allogeneic SCT for adult patients with
SCD is feasible, even in the setting of end-stage renal disease.












Renal Failure and SCD 549 5.9 5.3* 52 4093
Normal Renal Function-1 788 10.5 6.4 72.6 3972
Normal Renal Function-2 1170 9.2 6.4 59.6 4049
*calculated from dialysis phase slope; Cmax Maximum Concentra-
tion, t1/2 half life, CL clearance, Vss Steady State Volume of
Distribution, AUC Area under curve
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DONOR KILLER IG-LIKE RECEPTOR HAPLOTYPE IS ASSOCIATED WITH
LOWER RELAPSE IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS
UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION
Abarghoui, F.1, Pinto-Agnello, C.2, Gooley, T.3, Senitzer, D.4,
Malkki, M.3, Dupont, B.2, Petersdorf, E.3, Hsu, K.1, International
Histocompatibility Working Group.5 1Memorial Sloan-Kettering Cancer
Center, New York, NY; 2Sloan-Kettering Institute for Cancer Research,
New York, NY; 3Fred Hutchinson Cancer Research Center, Seattle, WA;
4City of Hope Cancer Center, Duarte, CA; 5International Histocompat-
ibility Working Group.
In allogeneic hematopoietic cell transplantation (HCT), do-
nor natural killer (NK) cells can prevent leukemia relapse and
prolong survival. NK alloreactivity has been shown to be inﬂu-
enced by the killer Ig-like receptor (KIR) repertoire of the
donor and the HLA class I KIR ligand phenotype of the recip-
ient. We sought to determine if more activating receptors in the
donor KIR repertoire would inﬂuence the outcome of alloge-
neic transplant for hematologic malignancies. Comprising 50%
of all haplotypes in the Caucasian population, KIR haplotype-A
is a conserved haplotype with nearly no activating KIR. In
contrast, haplotype-B comprises a variety of different haplo-
types, most of which contain several activating KIR. Using data
provided from the International Histocompatibility Working
Group, we studied the donor KIR genotypes from 541 unrelated
donor transplants and examined the impact of donor KIR hap-
lotype on overall surivival (OS) and relapse, by segregating
donor-recipient pairs into those in which the donor was ho-
mozygous for KIR haplotype A (AA) versus those in which the
donor was heterozygous or homozygous for the B-haplotype.
Models were adjusted for disease severity, HLA-mismatch, and
patient age. There was no survival advantage to having a donor
with a B haplotype compared to AA donors (HR 1.05, 95% CI
0.80-1.37, p0.73). However, there was a signiﬁcant effect of
donor B haplotype on relapse, where the presence of a donor B
haplotype (n330) compared to donor AA (n162) was associ-
ated with signiﬁcantly lower hazard of relapse (HR0.41, 95%
CI 0.33-0.67, p0.0001). The haplotype B effect on relapse was
overwhelming strong in transplants for CML (n189,
HR0.15, 95% CI 0.08-0.27, p0.0001). There was no signif-
icant donor B-haplotype effect on relapse in AML (n104, HR
0.80, 95% CI 0.40-1.63, p0.54) or ALL (n96, HR 0.76, 95%
CI 0.30-1.95, p0.57). There was no clear association between
any speciﬁc activating KIR and decreased relapse, nor was there
was an association between cumulative numbers of activating
KIRs and decreased relapse. These results suggest that the
association between haplotype B and decreased relapse in CML
may be related to factors other than activating KIR present or
associated with the B-haplotypes and absent in the A-haplotype.
These results have implications for donor selection in patients
with CML who are referred for allogeneic transplantation.
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ALLOGENEIC BLOOD AND MARROW TRANSPLANTATION IN THALAS-
SEMIA MAJOR CLASS 3: AN EXPERIENCE OF IRAN
Iravani, M.1, Ali Mogaddam, K.1, Nedaeifard, L.1, Khatami, F.1,
Gavamzadeh, A.1, Golibeygian, S.1, Bab Hadiashar, N.1, Jalili, M.1,
Tagipur, R.1, Gaffari, F.1, Mousavi, A.1 1Hematology-Oncology and
BMT Research Center, Tehran University of Medical Sciences, Tehran,
Islamic Republic of Iran.
Objective:Our aim for this study was to describe the outcome of
blood and marrow transplantation in patients with class 3 Thalas-
semia major.
Methods: Since December 1992 till september 2006, ﬁfty-two
patients with Thalassemia class 3 received blood and marrow
transplantation from their Human Leukocyte Antigen(HLA)-iden-
tical siblings. Thirty-two patients received bone marrow and
twenty patients received peripheral blood stem cell transplantation.
Conditioning regimen in 47 patients was Cyclophosphamide 40
mg/kg/day (from day–5 to -2) and Busulfan 3.5 mg/kg/day (from
day –9 to -6) and in these patients Graft Versus Host Disease
(GVHD) prophylaxis regimen was Cyclosporine.A (CY.A)
1.5mg/kg /day/IV (day–3), then 3mg/kg/day IV (days 7, 11),
then 12.5 mg/kg/day/PO and Methotrexate 10mg/m2 (day 1),
6mg/m
2
(days 3, 6). Conditioning regimen in 5 patients was
Fludarabin 40 mg/m2 (from –6 to –2) and Busulfan 4 mg/kg (from
–5 to –2) and in this patients GVHD prophylaxis regimen was
(CY.A) 3 mg/kg/day IV (days –3 and 7), then 12.5 mg/kg/day
PO.
Results: Median age at time of transplantation was 8.5 years
(age range: 1-26), Male/Female: 21/31.Median time of absolute
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neutrophil count  0.5109 /L was 14 and Median time of
platelet recovery 20109 /L was 25. At present 42 out of 52
are alive and 10 patients died due to acute GVHD, chronic
GVHD, rejection, veno-occlusive disease, infection and the
others. Thirty-four patients (64%) developed acute GVHD
(grade I  13, grade II  7, grade III 10, grade IV 4). Three
patients (5.8%) developed chronic GVHD (limited 2, exten-
sive 1). 8-year disease free survival were 73.17%. 8-year over-
all survival were 79.85%.
Conclusion: According to this study, for an acceptable out-
come in Thalassemia class 3We need better conditioning and
GVHD prophylaxis regimens to decrease cardiopulmonary and
liver complications. The results of blood and marrow transplan-
tation showed that it is better than supportive therapy such as
transfusion and desferal therapy.
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OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA IN
SECOND COMPLETE REMISSION, SINGLE CENTRE EXPERIENCE
Ishaqi, M.K.1, Afzal, S.1, Doyle, J.1, Gassas, A.1 1Division of Haema-
tology/Oncology/Bone Marrow Transplantation, Hospital for Sick Chil-
dren, University of Toronto, Canada, Toronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (HSCT) is
proven to be an effective modality of treatment for children with
high risk or relapsed acute myelogenous leukemia (AML). Sur-
vival rate as high as 72% has been reported when offered to
patients in ﬁrst complete remission (CR1). The outcome for
children transplanted in second complete remission is less
favourable with reported survival ranging from 40 to 58%. We
reviewed 26 consecutive pediatric patients with AML who re-
ceived allogeneic HSCT in CR2 between 1994 and 2005 in the
Hospital for Sick Children, Toronto, Canada. Twenty-two pa-
tients transplanted in CR2 after chemotherapy only relapse and
4 patients suffered relapse after ﬁrst allogeneic transplant and
received second allogeneic HSCT in CR2. Conditioning regi-
mens included cyclophosphamide 50mg/kg infused over 1 hour
daily for 4 days and fractionated total body irradiation (TBI;
1200cGy) in six fractions over 3 days (CY/TBI) in 13 patients,
2 patients received Busulfan infused every 6 hours for 4 days
followed by cyclophosphamide 50mg/kg infused over 1 hour
daily for 4 days (Bu/CY), 5 patients received ATG in addition to
the Bu/CY regimen and 6 patients received other conditioning
regimens. Median age at transplant was 8.3 years (range 2.2-18.2
years). Four patients received matched sibling donor (MSD), 5
patients received one antigen mismatched related donor
(MMRD), 16 patients received unrelated donors and 1 patient
received unrelated cord progenitor stem cells. Primary graft
failure was encountered in 2 patients, 1 patient was re-trans-
planted successfully and remains alive in remission and the other
patient died of sepsis and respiratory failure. The rest of the
patients engrafted at a median of 20 days (range 10-35 days).
Acute grade III-IV and chronic GVHD occurred in 9 patients
(35%). Six patients (23%) suffered relapse, 4 of them died and
two are still alive at 2495 days and 2944 days with donor
leukocyte infusion (DLI) and second transplantation, respec-
tively. Six patients (23.0%) died from TRM. Including the 2
relapsed patients who were salvaged by DLI and a second
transplantation, survival was 62% with a median follow-up of
1198 days (range 53-4014 days). Conclusion: Survival for chil-
dren transplanted in CR2 for AML is higher than previously
reported, but relapse and treatment-related mortality remains a
concern.
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NOVEL TYROSINE KINASE INHIBITOR THERAPY (NTKI) PRIOR TO
ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS
WITH CHRONIC MYELOID LEUKEMIA (CML): NO EVIDENCE FOR IN-
CREASED TRANSPLANT-RELATED TOXICITY
Jabbour, E.1, Cortes, J.1, Kantarjian, H.1, Giralt, S.1, Champlin, R.1,
de Lima, M.1 1University of Texas/MD Anderson Cancer Center,
Houston, TX.
Introduction: Patients undergoing ASCT for CML are increas-
ingly likely to have received a NTKI after failing imatinib mesy-
late. It is unknown whether the use of these NTKIs prior to ASCT
increases transplant-related toxicity.
Methods: We retrospectively analyzed the outcome of 12 pa-
tients with CML (1 chronic phase, 6 accelerated phase, and 5 in
blastic phase) who received dasatinib (n2), nilotinib (n7), or
both (n3) prior to ASCT.
Results: Median age was 41 years (range, 18-59 years). The
median time on treatment was 134 days (range, 30-285 days), and
the median time from the end of NTKI therapy to ASCT was 34
days (range, 7-130 days). Preparative regimen was ablative in 8
patients and non-ablative in 4. Source of stem cells were matched
related donors in 7 patients, matched unrelated in 3, haplo-iden-
tical in 1, and unrelated cord blood in 1. All patients engrafted
within 13 days. There was no signiﬁcant early transplant-related
toxicity: gastro-intestinal toxicities of grade 3 were encountered in
2 patients. One patient had secondary graft failure after 6 months
from the ﬁrst ASCT that required a second ASCT. Acute graft
versus host disease (GVHD) of grade 2 was observed in 7 patients
(58%), chronic GVHD in 6 (50%). Nine patients achieved a
molecular response: four complete and ﬁve major (Q-PCR
0.05%). Three patients had disease progression by day 30 post
ASCT. Two patients have relapsed after a median of 12 months
(range, 6-18 months). After a median follow-up of 10 months
(range, 3-22 months), 7 patients are alive in molecular response
and 5 patients died, 4 of disease progression and one of extensive
chronic GVHD.
Conclusion: Previous treatment with NTKI did not increase
transplant-related toxicity in this preliminary experience. Further
follow-up and larger number of patients will be necessary to con-
ﬁrm these observations.
249
A MIND AND PHYSICAL FITNESS PROGRAM IN CANCER CARE – FEA-
SIBILITY OF A MULTIMODAL EXERCISE AND PSYCHO-EDUCATIONAL
INTERVENTION FOR PATIENTS UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION. A RANDOMIZED CONTROLLED PILOT STUDY
Jarden, M.1,3, Hovgaard, D.2, Boesen, E.3, Adamsen, L.1 1The Uni-
versity Hospitals Center for Nursing and Care Research, University
Hospital of Copenhagen, Copenhagen, Denmark; 2University Hospital of
Copenhagen, Department of Hematology, Copenhagen, Denmark;
3Danish Cancer Society, Copenhagen, Denmark.
Background: A pilot study incorporating a multimodal ﬁtness
and psycho-educational program to patients undergoing allogeneic
stem cell transplant (allo-HSCT). The main focus of the study is to
evaluate the feasibility, safety and effectiveness of a 4-6 week
intervention consisting of a ﬁtness program with progressive sta-
tionary bicycle-, muscle strength-, ﬂexibility- and relaxation train-
ing and a cognitive based supportive and educational intervention.
The aim of the study was to prevent or minimize loss of physical
capacity and improve overall well being during hospitalization.
Patients and methods: 20 adult patients (18 -65 years) were
randomized to either an intervention or control group using the
clinical international trial management system.Through triangula-
tion of qualitative and quantitative methods, patients are inter-
viewed, tested for physical capacity (VO2 max, muscle strength and
physical functioning), quality of life (EORTC, HADS, Fact-An
and Mini-mac) prior to admission and upon discharge. Patients
kept training journals and registered side effects during hospital-
ization. This study reports only the ﬁndings from the physical
capacity tests.
Results and Conclusion
Of the 22 eligible patients who met the eligibility criteria, 20
agreed to participate (90.9%).14 of 20 patients (70%) completed
all study requirements. In the intervention group, 6 of 9 patients
completed all study requirements (66.7% retention rate). Ad-
herence to the intervention showed that patients trained 94% of
the total expected training days. No adverse reactions or events
that can be attributed to either the testing or exercise program
were reported or observed. Pre test scores showed similiar
values in both groups for all physical capacity tests. Upon
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